News | June 03, 2022
GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
